You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A potent and selective group III metabotropic glutamate receptor agonist, with approximately 25-fold preference for hmGlu8; anticonvulsant and neuroprotective in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 231.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.33 mL||21.63 mL||43.26 mL|
|5 mM||0.87 mL||4.33 mL||8.65 mL|
|10 mM||0.43 mL||2.16 mL||4.33 mL|
|50 mM||0.09 mL||0.43 mL||0.87 mL|
References are publications that support the biological activity of the product.
Bigge et al (1989) Exploration of phenyl-spaced 2-amino-(5,9)-phosphonoalkanoic acids as competitive N-MthD.-aspartic acid antagonists. J.Med.Chem. 32 1580 PMID: 2544728
Gasparini et al (1999) (R,S)-4-Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J.Pharmacol.Exp.Ther. 289 1678 PMID: 10336568
Flor et al (1998) Neuroprotection in vitro and in vivo by (R,S)-PPG, a potent and selective group III metabotropic glutamate receptor agonist. Soc.Neurosci.Abstr. 24 431.11
If you know of a relevant reference for (RS)-PPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-PPG, (RS)-PPG supplier, Potent, selective, mGlu8, mGluR8, agonist, Group, III, Receptors, Glutamate, Metabotropic, (Metabotropic), 1220, Tocris Bioscience
1 Citation for (RS)-PPG
Citations are publications that use Tocris products. Selected citations for (RS)-PPG include:
Kammermeier (2015) Constitutive activity of metabotropic glutamate receptor 7. Neuropharmacology 16 17 PMID: 25881041
Do you know of a great paper that uses (RS)-PPG from Tocris? Please let us know.
Reviews for (RS)-PPG
There are currently no reviews for this product. Be the first to review (RS)-PPG and earn rewards!
Have you used (RS)-PPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.